Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:03:41.414Z.
Calculation as of: 2026-10-06T16:03:41.414Z.
Quote observation: 2026-10-06T16:00:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 44fde230bfdd574c3cd4cd53b0628620ec84ec898484da9a9f15813d4ff0e801
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$593.86M
EV/EBIT Ratio
N/A
TTM Avg
2.85x
3Y Avg
52.42x
5Y Avg
52.42x
Market Cap
$573.38M
EV/EBIT Ratio
N/A
TTM Avg
78.65x
3Y Avg
78.65x
5Y Avg
78.65x
Market Cap
$600.84M
EV/EBIT Ratio
3.89x
TTM Avg
7.80x
3Y Avg
8.99x
5Y Avg
8.51x
Market Cap
$569.16M
EV/EBIT Ratio
N/A
TTM Avg
14.25x
3Y Avg
18.01x
5Y Avg
18.01x
Market Cap
$609.48M
EV/EBIT Ratio
N/A
TTM Avg
596.45x
3Y Avg
263.81x
5Y Avg
279.32x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OrthoPediatrics Corp. (KIDS) | $587.06M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $593.86M | N/A | 2.85x | 52.42x | 52.42x |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | N/A | 78.65x | 78.65x | 78.65x |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.84M | 3.89x | 7.80x | 8.99x | 8.51x |
| CytomX Therapeutics, Inc. (CTMX)vs › | $569.16M | N/A | 14.25x | 18.01x | 18.01x |
| CorMedix Inc. (CRMD)vs › | $566.81M | 2.10x | 6.25x | 15.98x | 15.98x |
| AngioDynamics, Inc. (ANGO)vs › | $609.48M | N/A | 596.45x | 263.81x | 279.32x |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $628.76M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $554.29M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
